Key facts
- This page summarizes Metin Kurtoglu's Form 4 filing for Cartesian Therapeutics, Inc. (RNAC).
- 7 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 11 Dec 2024, 16:28.
Metin Kurtoglu - 09 Dec 2024 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)
- Reporting relationship
- Chief Technology Officer
- Issuer ticker
- RNAC
- Reported as of
- 09 Dec 2024
- Net transaction value
- -$325,868
- SEC form
- 4
- Accepted by SEC
- 11 Dec 2024, 16:28:35 UTC
- Prior SEC filing
- 21 Nov 2024
- Next SEC filing
- 06 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Matthew Bartholomae, Attorney-in-Fact for Metin Kurtoglu
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Metin Kurtoglu filed Form 4 for Cartesian Therapeutics, Inc. (RNAC) on 11 Dec 2024.
Change
- Previous filing in this sequence was filed on 21 Nov 2024.
- Current net transaction value: -$325,868.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RNAC
transaction
Common Stock
Options Exercise
- Transaction value
- $15,176
- Shares
- +10,763
- Change %
- +21%
- Price
- $1.41
- Shares after
- 61,796
- Date
- 09 Dec 2024
- Ownership
- Direct
RNAC
transaction
Common Stock
Sale
- Transaction value
- $157,236
- Shares
- -6,224
- Change %
- -10%
- Price
- $25.26
- Shares after
- 55,572
- Date
- 09 Dec 2024
- Ownership
- Direct
- Footnotes
- F1
RNAC
transaction
Common Stock
Sale
- Transaction value
- $117,257
- Shares
- -4,539
- Change %
- -8.2%
- Price
- $25.83
- Shares after
- 51,033
- Date
- 09 Dec 2024
- Ownership
- Direct
- Footnotes
- F2
RNAC
transaction
Common Stock
Options Exercise
- Transaction value
- $4,090
- Shares
- +2,901
- Change %
- +5.7%
- Price
- $1.41
- Shares after
- 53,934
- Date
- 10 Dec 2024
- Ownership
- Direct
RNAC
transaction
Common Stock
Sale
- Transaction value
- $70,640
- Shares
- -2,901
- Change %
- -5.4%
- Price
- $24.35
- Shares after
- 51,033
- Date
- 10 Dec 2024
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RNAC
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -10,763
- Change %
- -12%
- Price
- Shares after
- 82,000
- Date
- 09 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 10,763
- Exercise price
- $1.41
- Footnotes
- F4, F5
RNAC
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -2,901
- Change %
- -3.5%
- Price
- Shares after
- 79,099
- Date
- 10 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,901
- Exercise price
- $1.41
- Footnotes
- F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.58 to $25.57. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $25.58 to $26.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.00 to $24.78. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
The option was fully vested and exercisable upon the closing of the merger described in footnote 5.
Footnote F5
On November 13, 2023, the Issuer acquired the private Delaware corporation which was then known as Cartesian Therapeutics, Inc. ("Old Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. Options to purchase Old Cartesian common stock held by the reporting person were converted into options to purchase shares of the Issuer's Series A Preferred Stock in connection with the merger. On April 8, 2024, these options previously exercisable for shares of Series A Preferred Stock became exercisable solely for shares of the Issuer's Common Stock.